POXEL
🏢 View company profile →13Patents
13Active
13Granted
46Portfolio score
Filing activity: Dec 11, 2009 → Apr 2, 2021 · 3 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9271984B2 | Treatment of type 1 diabetes | Human Necessities | 4 | Active |
| US8937066B2 | Amino derivatives of dihydro-1,3,5-triazine used in the treatment of ischemia and/or reperfusion related diseases | Human Necessities | 4 | Active |
| US9035048B2 | Tetrahydrotriazine compounds for treating diseases associated with AMPK activity | Human Necessities | 4 | Active |
| US8742103B2 | Separation of triazine derivatives enantiomers using tartaric acid | Emerging Cross-Sectional Technologies | 4 | Active |
| US8742102B2 | Process for enantiomeric separation of racemic dihydro-1,3,5 triazines via preferential crystallization | Human Necessities | 4 | Active |
| US8846911B2 | Process of isolating enantiomer components from enantiomer mixtures by particle-size-controlled crystallization | Chemistry; Metallurgy | 4 | Active |
| US9284329B2 | Thienopyridone derivatives useful as activators of AMPK | Human Necessities | 2 | Active |
| US9895380B2 | Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection | Human Necessities | 1 | Active |
| US12310949B2 | Use of a thienopyridone derivative in the treatment of autosomal dominant polycystic kidney disease (ADPKD) | Human Necessities | 0 | Active |
| US10071108B2 | Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection | Human Necessities | 0 | Active |
| US11850238B2 | Use of a thienopyridone derivative in the treatment of adrenoleukodystrophy or adrenomyeloneuropathy | Human Necessities | 0 | Active |
| US12319700B2 | Monohydrate potassium salt of a thienopyridone derivative and its preparation process | Human Necessities | 0 | Active |
| US9365584B2 | Thieno [2,3-B] pyridinedione activators of AMPK and therapeutic uses thereof | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.